Molecular Partners 
Welcome,         Profile    Billing    Logout  
 7 Products   1 Disease  7 Products   2 Trials   377 News 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ensovibep (MP0420) / AGC Biologics, Molecular Partners, Novartis
NCT05780463: MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Completed
3
485
Europe, US, RoW
MP0420, ensovibep, Placebo, Remdesivir, Veklury
National Institute of Allergy and Infectious Diseases (NIAID), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Medical Research Council, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, AIDS Clinical Trials Group, National Heart, Lung, and Blood Institute (NHLBI), US Department of Veterans Affairs, Prevention and Early Treatment of Acute Lung Injury, Cardiothoracic Surgical Trials Network, Molecular Partners AG, University of Minnesota
COVID-19
02/22
06/23
TICO, NCT04501978 / 2020-003278-37: ACTIV-3: Therapeutics for Inpatients With COVID-19

Completed
3
2753
Europe, US, RoW
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, AZD8895 + AZD1061, MP0420, ensovibep, PF-07304814
National Institute of Allergy and Infectious Diseases (NIAID), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Medical Research Council, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, AIDS Clinical Trials Group, National Heart, Lung, and Blood Institute (NHLBI), US Department of Veterans Affairs, Prevention and Early Treatment of Acute Lung Injury, Cardiothoracic Surgical Trials Network, Eli Lilly and Company, Vir Biotechnology, Inc., GlaxoSmithKline, Brii Biosciences Limited, AstraZeneca, Molecular Partners AG, Pfizer, University of Minnesota
Covid19
04/22
07/23
MP0317 / Molecular Partners
TACTIC, NCT07036380: MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma

Not yet recruiting
2
75
Europe
MP0317 + Gemcitabine + Cisplatine + Durvalumab, CT-Scan, Gemcitabine + Cisplatin + Durvalumab
Centre Hospitalier Universitaire de Besancon, Molecular Partners AG
Advanced Biliary Tract Carcinoma
06/28
06/29
MP0317-CP101, NCT05098405: First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors

Terminated
1
46
Europe
MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen), MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
Molecular Partners AG
Advanced Malignant Solid Tumor
01/24
01/24
MP0533 / Molecular Partners
2022-002432-31: A study of MP0533 in patients with blood cancer.

Not yet recruiting
1/2
75
Europe
MP0533, MP0533, Concentrate for solution for injection/infusion
Molecular Partners AG, Molecular Partners AG
relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), Diseases [C] - Cancer [C04]
 
 
MP0533-CP101, NCT05673057 / 2022-002432-31: Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recruiting
1/2
249
Europe
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, Part 2 - Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax, Part 2 - Arm B, MP0533 with Obinutuzumab pretreatment, Arm A, MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML, Arm B relapsed/refractory AML, MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients, Arm B in treatment naïve patients
Molecular Partners AG, Molecular Partners AG
Leukemia, Myeloid, Acute, Newly Diagnosed
12/27
12/29
DARPin-conjugated radioligand therapeutic / Novartis, Molecular Partners
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ensovibep (MP0420) / AGC Biologics, Molecular Partners, Novartis
NCT05780463: MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Completed
3
485
Europe, US, RoW
MP0420, ensovibep, Placebo, Remdesivir, Veklury
National Institute of Allergy and Infectious Diseases (NIAID), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Medical Research Council, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, AIDS Clinical Trials Group, National Heart, Lung, and Blood Institute (NHLBI), US Department of Veterans Affairs, Prevention and Early Treatment of Acute Lung Injury, Cardiothoracic Surgical Trials Network, Molecular Partners AG, University of Minnesota
COVID-19
02/22
06/23
TICO, NCT04501978 / 2020-003278-37: ACTIV-3: Therapeutics for Inpatients With COVID-19

Completed
3
2753
Europe, US, RoW
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, AZD8895 + AZD1061, MP0420, ensovibep, PF-07304814
National Institute of Allergy and Infectious Diseases (NIAID), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Medical Research Council, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, AIDS Clinical Trials Group, National Heart, Lung, and Blood Institute (NHLBI), US Department of Veterans Affairs, Prevention and Early Treatment of Acute Lung Injury, Cardiothoracic Surgical Trials Network, Eli Lilly and Company, Vir Biotechnology, Inc., GlaxoSmithKline, Brii Biosciences Limited, AstraZeneca, Molecular Partners AG, Pfizer, University of Minnesota
Covid19
04/22
07/23
MP0317 / Molecular Partners
TACTIC, NCT07036380: MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma

Not yet recruiting
2
75
Europe
MP0317 + Gemcitabine + Cisplatine + Durvalumab, CT-Scan, Gemcitabine + Cisplatin + Durvalumab
Centre Hospitalier Universitaire de Besancon, Molecular Partners AG
Advanced Biliary Tract Carcinoma
06/28
06/29
MP0317-CP101, NCT05098405: First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors

Terminated
1
46
Europe
MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen), MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
Molecular Partners AG
Advanced Malignant Solid Tumor
01/24
01/24
MP0533 / Molecular Partners
2022-002432-31: A study of MP0533 in patients with blood cancer.

Not yet recruiting
1/2
75
Europe
MP0533, MP0533, Concentrate for solution for injection/infusion
Molecular Partners AG, Molecular Partners AG
relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), Diseases [C] - Cancer [C04]
 
 
MP0533-CP101, NCT05673057 / 2022-002432-31: Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recruiting
1/2
249
Europe
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, Part 2 - Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax, Part 2 - Arm B, MP0533 with Obinutuzumab pretreatment, Arm A, MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML, Arm B relapsed/refractory AML, MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients, Arm B in treatment naïve patients
Molecular Partners AG, Molecular Partners AG
Leukemia, Myeloid, Acute, Newly Diagnosed
12/27
12/29
DARPin-conjugated radioligand therapeutic / Novartis, Molecular Partners
No trials found

Download Options